Top Page
GlaxoSmithKline
(LSE:GSK)
GlaxoSmithKline (GSK) vs. iShares MSCI United Kingdom ETF (EWC)
GlaxoSmithKline Business Overview & Revenue Model
GlaxoSmithKline Earnings Call Summary
GlaxoSmithKline Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.63B | 31.38B | 30.33B | 29.32B | 24.70B | 34.10B |
| Gross Profit | 22.68B | 21.90B | 21.25B | 19.46B | 16.34B | 23.12B |
| EBITDA | 9.08B | 6.67B | 9.14B | 8.63B | 6.45B | 10.16B |
| Net Income | 3.42B | 2.58B | 4.93B | 14.96B | 4.38B | 5.75B |
Balance Sheet | ||||||
| Total Assets | 59.26B | 59.46B | 59.01B | 60.15B | 79.10B | 80.43B |
| Cash, Cash Equivalents and Short-Term Investments | 3.62B | 3.89B | 5.69B | 7.88B | 4.33B | 6.37B |
| Total Debt | 17.35B | 16.99B | 18.02B | 20.99B | 24.17B | 27.15B |
| Total Liabilities | 44.90B | 46.38B | 46.21B | 50.05B | 57.76B | 59.62B |
| Stockholders Equity | 14.79B | 13.67B | 13.35B | 10.60B | 15.05B | 14.59B |
Cash Flow | ||||||
| Free Cash Flow | 5.20B | 3.57B | 4.42B | 5.14B | 5.02B | 6.20B |
| Operating Cash Flow | 7.72B | 6.55B | 6.77B | 7.40B | 7.95B | 8.44B |
| Investing Cash Flow | -3.62B | -1.23B | -1.59B | -8.77B | -1.78B | 2.16B |
| Financing Cash Flow | -3.60B | -4.73B | -5.64B | 823.00M | -7.59B | -10.13B |
GlaxoSmithKline Technical Analysis
GlaxoSmithKline Risk Analysis
GlaxoSmithKline Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £65.11B | 19.29 | 23.47% | 3.62% | 0.59% | -15.36% | |
77 Outperform | £11.69B | 31.76 | 9.30% | 2.08% | 2.51% | 56.56% | |
75 Outperform | £194.28B | 30.26 | 20.09% | 1.67% | 11.89% | 25.68% | |
74 Outperform | £3.86B | 13.53 | 15.66% | 3.63% | 3.73% | 27.13% | |
70 Outperform | £4.96B | 30.43 | 12.73% | 2.02% | 4.18% | 37.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
GlaxoSmithKline Corporate Events
GSK has announced the purchase of 248,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This move is part of a broader strategy initiated on September 30, 2025, which has seen the company repurchase over 5.3 million shares, aiming to enhance shareholder value and optimize capital structure. Following this transaction, GSK holds over 252 million shares in treasury, representing 6.22% of the company’s voting rights, a figure relevant for shareholder interest calculations under regulatory guidelines.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced positive results from its phase III clinical trials for a next-generation low carbon version of its Ventolin (salbutamol) metered dose inhaler (MDI). This new formulation, which uses an innovative low carbon propellant, shows therapeutic equivalence and safety comparable to the current version. If approved, it could reduce greenhouse gas emissions by 92% per inhaler, significantly impacting GSK’s carbon footprint and supporting global climate targets. The company plans to proceed with regulatory submissions, with a launch expected in 2026, offering a more sustainable option for patients with respiratory diseases.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK and Alector announced the results of the INFRONT-3 clinical trial for latozinemab, a treatment for frontotemporal dementia due to a progranulin gene mutation. While the trial showed a significant effect on plasma progranulin concentrations, it did not demonstrate clinical benefits in slowing disease progression, leading to the discontinuation of further studies. Despite this setback, GSK remains committed to exploring the data for future research opportunities in neurodegeneration.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the purchase of 250,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, part of a non-discretionary agreement, brings the total shares held in treasury to 252,578,344, representing 6.22% of the company’s voting rights. The buyback initiative is aimed at optimizing the capital structure and providing returns to shareholders, reflecting GSK’s strategic focus on enhancing shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the approval of Shingrix in a prefilled syringe format. This new presentation simplifies the administration process for healthcare professionals and is expected to receive marketing authorization in the EU by December 2025, potentially enhancing GSK’s market position in the shingles vaccine sector.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK and Spero Therapeutics announced promising results from the phase III PIVOT-PO trial for tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs). The trial demonstrated that tebipenem HBr is non-inferior to intravenous imipenem-cilastatin, offering a potential new oral option that could reduce hospital stays for cUTI patients. This development is significant given the high healthcare costs and serious risks associated with cUTIs, often caused by multidrug-resistant pathogens. If approved, tebipenem HBr would be the first oral carbapenem antibiotic in the US, enhancing GSK’s anti-infectives portfolio and addressing antimicrobial resistance challenges.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 220,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, reflects GSK’s strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held as treasury shares, increasing the total to 252,328,344, while the total number of voting rights remains at 4,063,088,575. This move may influence shareholder calculations regarding their interests in the company.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 414,000 of its own ordinary shares as part of its ongoing buyback program, with shares being held as treasury stock. This transaction, executed through BNP Paribas SA, reflects GSK’s strategic financial management aimed at optimizing shareholder value. Following this purchase, GSK holds a total of 252,108,344 ordinary shares in treasury, with 4,063,308,575 shares remaining in issue, impacting the voting rights percentage and potentially influencing shareholder decisions.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the purchase of 310,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through BNP Paribas SA, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds 251,694,344 shares in treasury, with a total of 4,063,719,485 shares in issue, excluding treasury shares. The buyback program reflects GSK’s commitment to returning value to shareholders and optimizing its capital allocation.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the acquisition of American Depositary Shares (ADSs) by key company executives, including Dr. Hal Barron, James Ford, and Shobie Ramakrishnan, following the reinvestment of dividends paid to shareholders. These transactions, conducted on the New York Stock Exchange, reflect the company’s ongoing commitment to aligning executive interests with shareholder value, potentially enhancing stakeholder confidence in GSK’s market strategies.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 405,500 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, completed on October 15, 2025, reflects GSK’s strategic approach to managing its capital structure and enhancing shareholder value. Following this purchase, GSK holds 251,384,344 shares in treasury, with a total of 4,064,029,485 shares in issue, excluding treasury shares. The buyback program is significant for stakeholders as it indicates GSK’s confidence in its financial stability and commitment to returning value to shareholders.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced an increase in notional interest in its ordinary shares for several key executives, including the CEO and CFO, following the reinvestment of dividends paid on October 9, 2025. This transaction, conducted on the London Stock Exchange, reflects the company’s ongoing commitment to aligning executive interests with shareholder value through its Deferred Annual Bonus Plan.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 270,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, part of a larger initiative since September 2025, aims to enhance shareholder value by reducing the number of shares in circulation, thereby potentially increasing the value of remaining shares. The company now holds 250,978,844 shares in treasury, with a total of 4,064,434,985 shares in issue, impacting the voting rights and shareholding calculations for stakeholders.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 340,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on October 13, 2025, reflects GSK’s strategy to manage its capital structure and enhance shareholder value, with the purchased shares being held as treasury shares. The buyback program is a significant move in maintaining the company’s market positioning and optimizing its financial operations.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced that its Shingrix vaccine has been approved by the China National Medical Products Administration for use in adults aged 18 and over who are at increased risk of shingles due to immunodeficiency or immunosuppression. This approval marks Shingrix as the first and only vaccine available for this demographic in China, expanding its existing indication for adults aged 50 and over. The approval is significant given the high incidence of shingles in China, with approximately six million cases annually, and it underscores GSK’s commitment to protecting vulnerable populations and enhancing healthcare systems’ focus on disease prevention.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of ordinary shares by several key executives, including the CEO and other senior leaders, through the reinvestment of dividends as part of the company’s Share Reward Plan. These transactions, conducted on the London Stock Exchange, reflect the company’s ongoing commitment to aligning the interests of its leadership with those of its shareholders, potentially impacting stakeholder confidence and market perception.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the purchase of 355,000 of its ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, conducted on October 10, 2025, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds a total of 250,368,844 shares in treasury, representing 6.16% of the voting rights, which may influence shareholder calculations under regulatory guidelines.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of ordinary shares by several of its key executives under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involves notable figures such as CEO Emma Walmsley and CFO Julie Brown, among others, and reflects GSK’s commitment to aligning the interests of its leadership with those of its shareholders.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 295,000 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through BNP Paribas SA, reflects the company’s strategy to manage its capital structure and enhance shareholder value, with the purchased shares held as treasury shares.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the purchase of 308,000 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through BNP Paribas SA, will be held as treasury shares. This transaction is part of a broader strategy to manage the company’s capital structure and return value to shareholders, with GSK having purchased a total of 2,254,000 shares since the end of September 2025. The buyback is expected to impact the company’s voting rights structure, with 6.14% of voting rights now attributable to treasury shares.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the purchase of 354,000 of its own ordinary shares as part of its ongoing buyback program. The shares, purchased at prices ranging from 1,597.50p to 1,611.50p, will be held as treasury shares. This move is part of a non-discretionary agreement with BNP Paribas SA, and since September 30, 2025, GSK has acquired a total of 1,946,000 shares. The company now holds 249,410,844 shares in treasury, with 4,065,997,695 shares in issue. This buyback strategy is likely aimed at optimizing capital structure and potentially enhancing shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 340,000 of its own ordinary shares as part of its ongoing buyback program. This move, executed through BNP Paribas SA, reflects the company’s strategy to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and this transaction increases the total number of shares held in treasury to 249,056,844, representing 6.12% of the company’s voting rights. This buyback is part of a broader initiative that has seen the company repurchase 1,592,000 shares since September 30, 2025, potentially impacting the company’s stock liquidity and market perception.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 350,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on October 3, 2025, is part of a broader strategy to optimize the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds a total of 248,716,844 shares in treasury, with the total number of voting rights in the company standing at 4,066,691,695. This move reflects GSK’s commitment to returning value to its shareholders and maintaining a strong market position.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 335,000 of its own ordinary shares as part of its ongoing buyback program, with the shares held as treasury stock. This move is part of a non-discretionary agreement with BNP Paribas SA and reflects the company’s strategy to manage its capital structure, potentially enhancing shareholder value and market confidence.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced its total voting rights and capital as of September 30, 2025. The company’s issued share capital consists of over 4.3 billion ordinary shares, with a total of approximately 4.07 billion voting rights available. This information is crucial for shareholders to determine their required notifications under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 305,000 ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, completed on September 30, 2025, reflects GSK’s strategic financial management to enhance shareholder value. The shares will be held as treasury shares, and following this purchase, GSK holds 247,769,844 shares in treasury, with a total of 4,067,637,496 shares in issue. This move is significant for stakeholders as it impacts the voting rights and share distribution, with treasury shares now accounting for 6.09% of the voting rights.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the commencement of the third tranche of its £2 billion share buyback programme, which aims to return excess capital to shareholders and enhance earnings per share. This tranche, valued at up to £0.3 billion, will be executed through a non-discretionary agreement with BNP Paribas and is expected to be completed by December 2025, reflecting GSK’s strategic focus on optimizing shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the appointment of Luke Miels as CEO Designate, who will take over full responsibilities as CEO from January 1, 2026. Miels, who has been with GSK since 2017 as Chief Commercial Officer, has played a key role in expanding the company’s specialty medicines portfolio. He will succeed Dame Emma Walmsley, who has significantly transformed GSK’s operations, including the creation of Haleon, a leader in consumer health. This leadership change marks a pivotal phase for GSK as it aims for long-term growth with sales expectations exceeding £40 billion by 2031.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of shares by several of its independent non-executive directors, including Wendy Becker, Elizabeth McKee Anderson, Charles Bancroft, Dr Hal Barron, Dr Anne Beal, Dr Hal Dietz, Dr Jeannie Lee, and Dr Vishal Sikka. These transactions, which took place on September 19, 2025, involved the acquisition of ordinary shares and American Depositary Shares (ADSs) on the London Stock Exchange and New York Stock Exchange, respectively. This move reflects the directors’ confidence in the company’s future prospects and may positively impact stakeholder perceptions.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 15,858 of its own ordinary shares as part of its ongoing buyback program, conducted through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement made in June 2025, aims to manage the company’s capital structure and potentially enhance shareholder value. Following this purchase, GSK holds 247,464,844 shares in treasury, with a total of 4,067,938,124 shares in issue, excluding treasury shares. The move reflects GSK’s strategic financial management and impacts its voting rights, which now stand at 6.08% for treasury shares.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 209,886 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on September 17, 2025, is part of a larger strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 247,448,986 shares in treasury, with a total of 4,067,953,982 shares in issue. The buyback is expected to enhance shareholder value and reflects the company’s confidence in its financial health and future prospects.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the repurchase of 210,377 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, reflects GSK’s strategic efforts to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and the company now holds a total of 247,239,100 ordinary shares in treasury. The buyback is part of a non-discretionary agreement and contributes to the company’s financial strategy, potentially impacting shareholder voting rights and market perceptions.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced a significant investment of $30 billion in the United States over the next five years, aimed at enhancing research and development and supply chain infrastructure. This includes a $1.2 billion investment in advanced manufacturing facilities and digital technologies, which will create hundreds of skilled jobs and strengthen the company’s presence in the U.S. life sciences sector. The initiative highlights GSK’s commitment to innovation and its strategic focus on respiratory and cancer medicines, further solidifying its leadership in the biopharma industry.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 253,331 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, part of a non-discretionary agreement initiated in June 2025, brings the total number of shares held in treasury to 247,028,723, representing 6.07% of the company’s voting rights. The buyback strategy is aimed at optimizing the capital structure and returning value to shareholders, potentially impacting the company’s stock market performance and investor relations.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 203,447 of its own ordinary shares as part of an ongoing buyback program, with the shares to be held in treasury. This transaction, executed through Merrill Lynch International, reflects GSK’s strategy to manage its capital structure and return value to shareholders. Following this purchase, GSK holds 246,775,392 shares in treasury, representing 6.07% of the voting rights, which may impact shareholder calculations under regulatory guidelines.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 205,355 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction is part of a non-discretionary agreement initiated in June 2025, and the shares will be held as treasury shares. The buyback program reflects GSK’s strategy to manage its capital structure and enhance shareholder value, with the company now holding 246,571,945 shares in treasury. The total number of voting rights in the company remains at 4,068,829,782.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the purchase of 205,355 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on the London Stock Exchange, is part of a non-discretionary agreement established in June 2025, and it contributes to the company’s strategy to manage its capital structure effectively, impacting the voting rights and shareholding structure.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the repurchase of 213,147 of its ordinary shares as part of its ongoing buyback program, executed through its broker Merrill Lynch International. This transaction is part of a larger strategy initiated in June 2025, which has seen the company repurchase over 28 million shares. The shares will be held as treasury shares, affecting the company’s voting rights and share capital structure. This move is likely to impact shareholder value and market perception positively, as buybacks often signal confidence in the company’s financial health.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of ordinary shares by several key executives under the company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of shares by the CEO, CFO, and other senior executives, reflecting their commitment to the company’s growth and aligning their interests with shareholders.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 207,767 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which forms part of a non-discretionary agreement, increases the company’s treasury shares to 246,153,443, representing 6.05% of the voting rights. The buyback is part of GSK’s strategy to manage its capital structure and return value to shareholders.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 219,116 of its own ordinary shares as part of its ongoing buyback program. This transaction, conducted through Merrill Lynch International, is part of a non-discretionary agreement and contributes to the company’s efforts to manage its capital structure, potentially impacting shareholder value and market perception.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the repurchase of 219,116 of its ordinary shares as part of its ongoing buyback program. The shares were bought at a volume-weighted average price of 1,460.93 pence per share and will be held as treasury shares. This move is part of a non-discretionary agreement with Merrill Lynch International and reflects GSK’s strategy to manage its capital structure effectively. The repurchase increases the total number of shares held in treasury to 245,945,676, representing 6.04% of the company’s voting rights, which could impact shareholder calculations under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 276,710 ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This move is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this transaction, GSK now holds 245,726,560 shares in treasury, with a total of 4,069,675,167 shares in issue, affecting the voting rights and potentially impacting shareholder decisions.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 284,800 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement, increases the company’s treasury shares to 245,449,850, with a total of 4,069,946,246 shares in issue. The buyback is a strategic move to manage the company’s capital structure and potentially enhance shareholder value by reducing the number of shares available in the market.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1434.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced a transaction involving the award of ordinary shares to Victoria Whyte, the Senior Vice President and Company Secretary, under the company’s 2025 Share Value Plan. This transaction, which involved 10,050 shares at a price of £14.4250 each, reflects GSK’s ongoing commitment to aligning its leadership’s interests with shareholder value, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1434.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the repurchase of 232,912 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. The shares were acquired at prices ranging from 1,445.50p to 1,466.00p per share and will be held as treasury shares. This transaction is part of a larger strategy to manage the company’s capital structure and return value to shareholders, with GSK holding a total of 245,165,050 shares in treasury and 4,070,231,046 shares in issue.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the purchase of 296,202 of its own ordinary shares as part of its ongoing buyback program. These shares, acquired through Merrill Lynch International, will be held as treasury shares, contributing to the company’s strategy to manage its capital structure and enhance shareholder value. Following this transaction, GSK holds 244,932,138 ordinary shares in treasury, representing 6.02% of the voting rights, while 4,070,463,958 shares remain in issue.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the purchase of 227,465 of its own ordinary shares as part of its ongoing buyback program. The shares, bought at prices ranging from 1,442.00p to 1,468.50p, will be held as treasury shares. This transaction, executed through Merrill Lynch International, increases GSK’s total treasury shares to 244,635,936, impacting the company’s voting rights and potentially influencing shareholder interests.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced its total voting rights and capital as of August 31, 2025, which includes an issued share capital of over 4.3 billion shares, with a significant portion held in Treasury. The total number of voting rights stands at approximately 4.07 billion, a crucial figure for shareholders to determine their notification obligations under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the purchase of 252,588 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on August 29, 2025, is part of a larger effort to manage the company’s capital structure, with the purchased shares held as treasury shares. Following this purchase, GSK holds 244,408,471 shares in treasury, with a total of 4,070,987,625 shares in issue. The buyback program is a strategic move to enhance shareholder value and optimize the company’s financial position.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) plc has announced the purchase of 252,588 of its own ordinary shares as part of its ongoing buyback program. The shares, purchased through Merrill Lynch International, will be held as treasury shares, contributing to a total of 244,408,471 shares in treasury and 4,070,987,625 shares in issue. This move is part of a non-discretionary agreement made earlier in the year and reflects GSK’s strategic financial management efforts.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 260,986 of its own ordinary shares as part of its ongoing buyback program. The shares were acquired through Merrill Lynch International and will be held as treasury shares. This transaction is part of a larger strategy initiated on June 4, 2025, which has seen the company purchase over 25 million shares. The buyback is intended to optimize the capital structure and enhance shareholder value, with the current treasury shares representing 5.99% of the company’s voting rights.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 251,452 ordinary shares as part of its ongoing share buyback program, executed through Merrill Lynch International. The shares, bought at prices ranging from 1,460.00p to 1,487.50p, will be held as treasury shares, increasing GSK’s total treasury holdings to 243,658,730 shares. This move is part of a strategy to manage the company’s capital structure and return value to shareholders, reflecting GSK’s commitment to optimizing shareholder returns.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 243,639 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on August 22, 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders, with the repurchased shares held in treasury. The buyback program reflects GSK’s commitment to enhancing shareholder value and optimizing its financial resources.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the repurchase of 238,918 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, part of a non-discretionary agreement, increases the total number of shares held in treasury to 243,163,639, representing 5.97% of the company’s voting rights. The buyback is part of GSK’s strategy to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced a transaction involving its Chief Digital and Technology Officer, Shobie Ramakrishnan, who will receive a cash payment following the vesting of an award under the GlaxoSmithKline Deferred Investment Award Programme. This transaction reflects the company’s ongoing commitment to rewarding its key personnel and may have implications for its financial management and stakeholder engagement.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the purchase of 214,694 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, is part of a non-discretionary agreement and aims to enhance shareholder value by holding these shares in treasury. The buyback program reflects GSK’s strategic focus on optimizing capital allocation and maintaining financial flexibility.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the repurchase of 211,358 of its ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. The shares, bought at prices ranging from 1,430.50p to 1,452.50p, will be held as treasury shares, contributing to a total of 242,710,027 shares in treasury. This move is part of a strategic effort to manage the company’s capital structure and enhance shareholder value, with the total number of voting rights in the company now standing at 4,072,681,707.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the acquisition of American Depositary Shares (ADSs) by two of its executives, Dr. Hal Barron and James Ford, through reinvestment of dividends in their respective savings plans. These transactions, conducted on the New York Stock Exchange, reflect the company’s ongoing commitment to aligning executive interests with shareholder value, potentially enhancing stakeholder confidence in GSK’s financial strategies.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £1610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the purchase of 221,293 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on the London Stock Exchange, reflects GSK’s strategic financial management and aims to optimize capital allocation, potentially enhancing shareholder value. Following this purchase, GSK holds 242,498,669 ordinary shares in treasury, with a total of 4,072,893,065 shares in issue, affecting the percentage of voting rights attributable to treasury shares.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 436,588 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which is part of a non-discretionary agreement, increases the total number of shares held in treasury to 242,277,376, representing 5.95% of the company’s voting rights. The buyback is intended to optimize the capital structure and return value to shareholders, reflecting GSK’s confidence in its financial health and future prospects.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) and iTeos Therapeutics are conducting a Phase 2 study titled A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer. The study aims to evaluate the efficacy and safety of novel immunotherapy combinations compared to monotherapy in patients with high PD-L1 expression in advanced non-small cell lung cancer (NSCLC). This research is significant as it explores potential new treatments for a challenging cancer type.
GlaxoSmithKline (GSK) has announced the repurchase of 501,689 of its ordinary shares as part of its ongoing buyback program. The shares, purchased through Merrill Lynch International, will be held as treasury shares. This transaction is part of a non-discretionary agreement initiated on June 4, 2025, and contributes to the total of 23,706,405 shares repurchased since that date. The buyback program aims to manage the company’s capital structure effectively, impacting the total number of voting rights, which stands at 4,073,550,458.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a larger effort that has seen the company buy back over 23 million shares since June 2025. The purchased shares will be held as treasury shares, and this move is expected to impact the company’s share capital structure by adjusting the number of voting rights, which now stands at 4,074,052,147.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 495,245 of its own ordinary shares as part of its ongoing buyback program, executed through its broker, Merrill Lynch International. This transaction, which took place on 12 August 2025, is part of a larger initiative that has seen the company repurchase over 22 million shares since June 2025. The shares will be held as treasury shares, impacting the company’s voting rights and share capital structure, with implications for shareholder interests and market positioning.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of 18 ordinary shares at a price of £14.0845 per share by each executive. This move reflects the company’s commitment to aligning the interests of its leadership with those of its shareholders, potentially strengthening stakeholder confidence and reinforcing GSK’s market position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK plc has announced the purchase of 494,426 of its own ordinary shares as part of an ongoing buyback program, executed through Merrill Lynch International. This transaction is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value, with the purchased shares being held as treasury shares. The buyback program reflects GSK’s confidence in its financial health and its commitment to delivering value to its shareholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 497,923 of its own ordinary shares as part of its ongoing share buyback program, executed through Merrill Lynch International. This transaction, which took place on August 8, 2025, reflects GSK’s strategic efforts to manage its capital structure and return value to shareholders. The shares were acquired at prices ranging from 1,389.50p to 1,405.50p and will be held as treasury shares, contributing to a total of 240,042,950 shares held in treasury. This move is part of a broader plan initiated on June 4, 2025, and highlights GSK’s commitment to enhancing shareholder value while maintaining a robust financial position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that the US FDA has accepted gepotidacin for priority review as an oral treatment for uncomplicated urogenital gonorrhoea, with a decision expected in December 2025. This new antibiotic option could replace current injectable treatments, addressing a significant public health need as gonorrhoea is a priority pathogen with rising resistance to existing therapies.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER). The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or with a PD-1 inhibitor, in treating aggressive solid tumors with specific genetic traits.
GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM). The study aims to evaluate whether the BRd combination can prolong progression-free survival and improve minimal residual disease negative status compared to the DRd regimen in patients with TI-NDMM.
GlaxoSmithKline (GSK) is currently conducting a Phase 2/3 clinical study titled ‘A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease.’ The primary goal is to assess the effectiveness and safety of belimumab, a biological treatment, in improving lung function and addressing other symptoms in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This study is significant as it could offer a new therapeutic option for a condition with limited treatments.
GlaxoSmithKline (GSK) and iTeos Therapeutics are conducting a Phase 3 clinical trial titled ‘GALAXIES Lung-301’ to assess the safety and efficacy of belrestotug combined with dostarlimab versus pembrolizumab with placebo in patients with high PD-L1 non-small-cell lung cancer (NSCLC). The study aims to determine if the new combination improves progression-free survival and overall survival compared to the current standard treatment.
GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled ‘A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer.’ The study aims to evaluate the efficacy of perioperative dostarlimab compared to the standard of care in patients with specific types of colon cancer, highlighting its potential significance in improving treatment outcomes.
GlaxoSmithKline (GSK) is conducting a Phase 3 study in India to assess the immune response and safety of their RSVPreF3 OA investigational vaccine. The study targets older adults aged 60 and above, as well as adults aged 50-59 at increased risk of respiratory syncytial virus lower respiratory tract disease (RSV-LRTD). The goal is to evaluate the vaccine’s effectiveness in preventing RSV-LRTD in these populations.
GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Controlled, Partially Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety and the Occurrence of RSV Associated Respiratory Tract Illness After Administration of a Single Dose of GSK’s RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Older. The study aims to assess the immune response and safety of the RSVPreF3 OA vaccine in adults aged 60 and older, with a focus on comparing results between participants in China and those from other countries.
GlaxoSmithKline (GSK) has recently completed a Phase 2b clinical study titled ‘A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (>=18 Years of Age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses and Compared to Healthy Controls (>=50 Years of Age)’. The study aimed to assess the immune response and safety of the RSVPreF3 OA vaccine in immunocompromised adults who have received lung or kidney transplants, as well as in healthy adults aged 50 and above. This research is significant as it explores the potential of the vaccine to enhance immune response in vulnerable populations.
GlaxoSmithKline (GSK) has announced the purchase of 502,466 of its own ordinary shares as part of its ongoing buyback program, executed through its corporate stockbroker Merrill Lynch International. This transaction is part of a non-discretionary agreement made on June 4, 2025, and contributes to the total of 21,410,644 shares purchased since that date. The purchased shares will be held as treasury shares, and this move is expected to impact the company’s share capital structure by maintaining a percentage of voting rights attributable to treasury shares at 5.88%.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced a settlement with CureVac and BioNTech regarding mRNA patent litigation, resulting in a $370 million upfront payment and a 1% royalty on future US sales of mRNA vaccines by Pfizer and BioNTech. This settlement, which will be recorded in GSK’s financial results, does not affect GSK’s ongoing patent enforcement against Pfizer and BioNTech in the US and Europe, and includes a tender agreement for GSK’s CureVac shares.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) is conducting a study titled ‘A Phase1b/2, Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors.’ The study aims to assess the safety and effectiveness of GSK5764227, a new biological treatment, in patients with advanced gastrointestinal cancers that cannot be surgically removed. This research is significant as it targets a patient group with limited treatment options.
GlaxoSmithKline (GSK) is conducting a Phase IIb clinical study titled A Phase IIb, Randomized, Observer-Blind Study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents. The study aims to evaluate the safety, tolerability, and immunogenicity of the MenABCWY vaccine, which targets five meningococcal serogroups to prevent invasive meningococcal disease (IMD) in adolescents.
GlaxoSmithKline (GSK) is conducting a clinical study titled ‘Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)’. The study aims to find the most tolerated dose of cobolimab and dostarlimab in children and young adults with advanced solid tumors, assess safety, manage side effects, and evaluate treatment effects.
GlaxoSmithKline (GSK) is currently conducting a Phase 3b clinical study titled An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study. The study aims to determine the optimal revaccination timing for the RSVPreF3 OA vaccine, assess long-term immune persistence and safety over five RSV seasons, and provide the vaccine to participants who previously received a placebo.
GlaxoSmithKline (GSK) has announced a new clinical study titled A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Participants With dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer in China (China RUBY). The study aims to evaluate the effectiveness and safety of dostarlimab in combination with chemotherapy drugs carboplatin and paclitaxel in treating endometrial cancer (EC) among Chinese participants. This research is significant as it seeks to improve treatment outcomes for EC, focusing on drug behavior and immune response.
GlaxoSmithKline (GSK) recently completed a Phase 1/2 clinical study titled ‘Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.’ The study aimed to evaluate the safety, efficacy, and immunogenicity of the NgG investigational vaccine compared to a placebo in healthy adults. This study is significant as it represents a first-in-human proof of concept for potentially preventing Neisseria gonorrhoeae infections.
GlaxoSmithKline (GSK) is currently recruiting for a Phase 2 study titled ‘A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis.’ The study aims to assess the efficacy and safety of combining momelotinib and luspatercept in patients with transfusion-dependent myelofibrosis, a condition where patients require regular blood transfusions. This research is significant as it targets both JAK inhibitor-naïve and experienced patients, potentially offering a new treatment avenue.
GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled ‘A Randomized, Open-label, Multi-center, Interventional Phase 3 Study of the Efficacy and Safety of Tafenoquine Compared to Primaquine (Both Co-administered With Chloroquine) for the Radical Cure (Relapse Prevention) of Plasmodium Vivax (P. Vivax) Malaria in Indian Participants (Pediatric and Adult Population)’. The study aims to gather efficacy and safety data to support the registration of tafenoquine in India, targeting the treatment of P. Vivax malaria.
GlaxoSmithKline (GSK) is currently conducting a Phase 4 clinical study titled A Phase 4, Single-arm, Open-label, Multi-center Study to Assess the Immune Response and Safety of the Meningococcal Group B Vaccine MenB+OMV NZ When Administered to Healthy Infants From 2 Months of Age in the Republic of Korea. The study aims to evaluate the safety and immune response of the rMenB+OMV NZ vaccine in infants, marking a significant step in ensuring the vaccine’s efficacy and safety for young children.
GlaxoSmithKline (GSK) is conducting a clinical study titled ‘A Seamless Phase 1/2, Observer-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Immunogenicity of a UTI Vaccine When Administered to Adults 18 Through 64 Years of Age and Clinical Efficacy When Administered to Females 18 Through 64 Years of Age.’ The study aims to evaluate the safety, immune response, and preliminary clinical efficacy of a urinary tract infection (UTI) vaccine in adults aged 18-64, with a focus on females.
GlaxoSmithKline (GSK) is conducting a study titled A Randomised, Double Blind, Placebo-controlled, Single Ascending Dose, Phase 1a/1b Multi-centre Study in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4771261. The study aims to assess the safety and effects of GSK4771261, a new drug, on both healthy individuals and those with autosomal dominant polycystic kidney disease (ADPKD).
GlaxoSmithKline (GSK) is conducting a study titled ‘A Prospective Study to Evaluate the Safety, Effectiveness and Impact of the RTS, S/AS01E Vaccine in Young Children in Sub-Saharan Africa.’ The study aims to assess the safety and efficacy of the RTS, S/AS01E malaria vaccine, which is intended to protect young children in sub-Saharan Africa as part of routine immunization programs. This study is significant as it evaluates the vaccine’s impact on children’s health in a region heavily affected by malaria.
GlaxoSmithKline (GSK) is conducting a Phase 3b study titled A Phase 3b, Open-Label, Multi-Center Study to Assess the Immune Response And Safety of The Meningococcal Group B Vaccine Rmenb+Omv Nz When Administered to Healthy Participants Aged 10 To 20 Years Old, Who Were Primed During the First 2 Years Of Life. The study aims to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ, in adolescents and young adults who were initially vaccinated as infants. This research is significant as it seeks to confirm whether a booster dose enhances immunity in previously vaccinated individuals compared to those who have never received the vaccine.
GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)’. The study aims to evaluate the efficacy of niraparib combined with pembrolizumab as a maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC) who have responded to initial chemotherapy. The primary focus is on improving progression-free survival and overall survival rates.
GlaxoSmithKline (GSK) is conducting a Phase 2, single-arm, open-label study titled ‘A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer.’ The study aims to evaluate the effectiveness of dostarlimab monotherapy in patients with untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. The primary objective is to determine if dostarlimab can serve as a standalone treatment, potentially allowing patients to avoid chemotherapy, radiation, and surgery.
GlaxoSmithKline (GSK) has announced the purchase of 504,016 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, conducted on August 6, 2025, is part of a non-discretionary agreement with the broker and contributes to the company’s strategy of managing its capital structure. The shares will be held as treasury shares, and following this purchase, GSK holds 239,042,561 ordinary shares in treasury, with a total of 4,076,345,924 ordinary shares in issue. This move is significant for shareholders as it impacts the voting rights and shareholding calculations under the Financial Conduct Authority’s rules.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) is conducting a significant clinical study titled A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD). The study aims to assess the efficacy and safety of belimumab, a biological treatment, in improving lung function and other symptoms in patients with systemic sclerosis associated interstitial lung disease. This research is crucial as it explores a potential new treatment avenue for a condition with limited options.
GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled ‘A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)’. The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or combined with a PD-1 inhibitor, in reducing tumor size in participants with specific genetic tumor characteristics.
GlaxoSmithKline (GSK) is conducting a Phase 3 study titled A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM). The study aims to determine if the BRd combination can extend progression-free survival and improve minimal residual disease negative status compared to the DRd combination in patients with newly diagnosed multiple myeloma who cannot undergo stem cell transplantation.
GlaxoSmithKline (GSK) is initiating a clinical study titled ‘A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of An Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age.’ The study aims to assess the safety and immune response of a new vaccine, Pn-MAPS30plus, designed to protect against multiple serotypes of the S. pneumoniae bacteria, potentially offering broader protection than existing vaccines.
GSK has announced the repurchase of 498,759 of its own shares as part of its ongoing buyback program, facilitated through Merrill Lynch International. This transaction, executed on August 5, 2025, reflects the company’s strategy to manage its capital structure effectively. The shares will be held as treasury shares, and this move increases the total number of shares held in treasury to 238,538,545, representing 5.85% of the voting rights. This buyback is part of a broader effort to enhance shareholder value and optimize the company’s financial resources.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) is conducting a Phase 3b study titled A Phase 3b, Randomized, Open Label, Multicountry, Multi-center, Extension and Crossover Vaccination Study to Evaluate the Immunogenicity and Safety of Different Revaccination Schedules and Persistence of a Single Dose of the RSVPreF3 OA Vaccine in Adults Aged 60 Years and Above Who Participated in the RSV OA=ADJ-006 Study. The study aims to determine the optimal timing for revaccination, assess long-term immune persistence, and provide the RSVPreF3 OA vaccine to participants who initially received a placebo. This research is significant as it targets respiratory syncytial virus (RSV) prevention in older adults.
GlaxoSmithKline (GSK) is conducting a clinical study titled ‘A Phase1b/2, Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors.’ The study aims to assess the safety and effectiveness of GSK5764227, a new biological treatment, in patients with advanced gastrointestinal cancers that cannot be surgically removed. This research is significant as it targets a patient group with limited treatment options.
GSK has announced the repurchase of 499,189 of its ordinary shares as part of its ongoing buyback program. The shares were purchased at a volume-weighted average price of 1,391.81 pence and will be held as treasury shares. This transaction is part of a non-discretionary agreement with Merrill Lynch International, aiming to optimize the capital structure and return value to shareholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 496,176 of its own ordinary shares, which will be held as treasury shares, as part of its ongoing buyback program. This move, executed through Merrill Lynch International, reflects GSK’s strategy to manage its capital structure and return value to shareholders, potentially impacting the company’s stock value and market perception.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced a new clinical study titled ‘Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC).’ This study aims to evaluate the efficacy and safety of GSK5764227, a novel treatment targeting B7-H3 proteins on cancer cells, in comparison to the standard treatment, topotecan. The study’s significance lies in its potential to improve outcomes for patients with relapsed SCLC by reducing tumor size and extending survival.
Study Overview: GlaxoSmithKline (GSK) is conducting a Phase 3 multicenter, randomized, double-blind study titled B-Well 1 to assess the efficacy and safety of Bepirovirsen in participants with chronic Hepatitis B who are already receiving nucleos(t)ide analogue treatment. The study aims to confirm the suppression of hepatitis B virus surface antigen (HBsAg) and evaluate the safety and pharmacokinetic profile of Bepirovirsen, highlighting its potential significance in treating chronic Hepatitis B.
GlaxoSmithKline (GSK) is conducting a study titled ‘REIMAGINE – Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study’. The study aims to assess the effectiveness of Mepolizumab in achieving clinical remission in patients with severe asthma characterized by an eosinophilic phenotype. This research holds significant potential for improving treatment outcomes for asthma patients.
GSK plc announced its total voting rights and capital structure as of July 31, 2025, in compliance with the Financial Conduct Authority’s rules. The company reported an issued share capital of over 4.3 billion shares, with a total of approximately 4.08 billion voting rights available. This information is crucial for shareholders to determine their interests and obligations under regulatory guidelines.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 474,100 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, GSK holds 237,044,421 shares in treasury, representing 5.81% of the voting rights. The buyback program reflects GSK’s commitment to returning value to shareholders and optimizing its financial position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 474,100 of its own ordinary shares as part of its ongoing buyback program. This transaction, executed through Merrill Lynch International, aims to enhance shareholder value and manage the company’s capital structure effectively. Following this purchase, GSK holds 237,044,421 shares in treasury, with a total of 4,078,340,989 shares in issue, impacting the voting rights and shareholding calculations for stakeholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £22.90 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) is conducting a Phase 4 clinical study titled ‘A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus.’ The study aims to evaluate the short-term and long-term efficacy and safety of Belimumab in adults with early systemic lupus erythematosus (SLE) who have ongoing disease activity despite stable initial therapy. This study is significant as it seeks to provide insights into managing SLE, a chronic autoimmune disease.
GlaxoSmithKline (GSK) plc, a major player in the pharmaceutical industry, has announced the purchase of 288,978 of its own ordinary shares, as part of its ongoing share buyback program. The shares were acquired through Merrill Lynch International, with prices ranging from 1,386.50p to 1,463.50p per share. This move is part of GSK’s strategy to manage its capital structure and return value to shareholders. Following this transaction, GSK holds 236,570,321 shares in treasury, with a total of 4,078,815,089 shares in issue, excluding treasury shares. The percentage of voting rights attributable to the shares held in treasury is now 5.80%.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £22.90 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced the repurchase of 490,615 of its own shares as part of its ongoing buyback program, executed through its broker Merrill Lynch International. This transaction is part of a larger initiative that has seen the company buy back over 18 million shares since June 2025, reflecting GSK’s strategy to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK reported strong financial performance in Q2 2025, driven by significant growth in its Specialty Medicines and Vaccines segments, with sales reaching £8.0 billion. The company achieved major milestones in its R&D pipeline, including several new product approvals and ongoing development of promising treatments in oncology and respiratory diseases. GSK has revised its 2025 financial guidance upwards, expecting growth towards the top end of its previous estimates, and continues to focus on shareholder returns through dividends and a share buyback program.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) is currently conducting a Phase 4 clinical study titled ‘A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus.’ The study aims to evaluate the short-term and long-term efficacy and safety of Belimumab in adults with early systemic lupus erythematosus (SLE) who continue to experience disease activity despite stable initial therapy. This research is significant as it could offer a new treatment avenue for patients with this challenging autoimmune condition.
GSK announced the purchase of 490,978 of its own ordinary shares as part of its ongoing buyback program. This move, executed through Merrill Lynch International, aims to manage the company’s capital structure and potentially enhance shareholder value. The shares will be held in treasury, and following this transaction, GSK holds a total of 235,790,728 shares in treasury, representing 5.78% of the voting rights. This strategic buyback is part of a broader effort to optimize financial performance and maintain a favorable market position.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) is conducting a long-term study titled ‘Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants With Moderate to Severe Atopic Dermatitis.’ The study aims to assess the safety and efficacy of GSK1070806, a drug designed for individuals with moderate to severe atopic dermatitis who have previously completed a phase 2b parent study.
GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease. The study aims to evaluate whether belimumab, administered subcutaneously, can stabilize or improve lung function in adults with interstitial lung disease (ILD) linked to connective tissue diseases (CTD), while maintaining an acceptable safety profile. This research is significant as ILD severely impacts quality of life and is a leading cause of death in affected individuals.
GlaxoSmithKline (GSK) is conducting a Phase 2b study titled ‘A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)’. The study aims to evaluate the safety and efficacy of sequential therapy using two different doses of DAP/TOM followed by bepirovirsen in patients with chronic Hepatitis B who are already on standard nucleos(t)ide analogue therapy. The goal is to identify the optimal dose for further clinical development and assess the contribution of DAP/TOM to the treatment regimen.
GSK has entered into agreements with Hengrui Pharma to develop up to 12 innovative medicines in the fields of Respiratory, Immunology & Inflammation, and Oncology, with a significant focus on a potential best-in-class PDE3/4 inhibitor for COPD treatment. This collaboration, which includes a $500 million upfront payment and potential future milestone payments of up to $12 billion, aims to leverage GSK’s global scale and Hengrui’s early discovery capabilities to accelerate the development and commercialization of these therapies, potentially enhancing GSK’s market position and offering new treatment options for patients worldwide.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) is conducting a Phase 2 clinical trial titled ‘A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer.’ The study aims to evaluate the effectiveness of dostarlimab combined with carboplatin-paclitaxel, followed by dostarlimab monotherapy, in treating endometrial cancer. This research is significant as it explores potential new treatment options for a challenging cancer type.
GlaxoSmithKline (GSK) recently completed a Phase I/II clinical study titled ‘A Phase I/II, Observer-blind, Randomised, Placebo-controlled, Multi-country Study to Evaluate Reactogenicity, Safety, Immune Response, and Efficacy of an HSV-targeted Immunotherapy in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes.’ The study aimed to assess the safety, immune response, and efficacy of a new immunotherapy targeting the herpes simplex virus (HSV) in both healthy individuals and those with recurrent genital herpes.
Study Overview: GlaxoSmithKline is conducting a Phase I/II study titled ‘A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 – Sub-study 3 – Belantamab Mafodotin and Nirogacestat in Combination.’ The study aims to assess the safety and tolerability of belantamab mafodotin combined with nirogacestat in patients with relapsed/refractory multiple myeloma, with the goal of establishing a recommended Phase 2 dose.
GlaxoSmithKline (GSK) is set to embark on a Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of its new 4-component vaccine against Group A Streptococcus Pyogenes (Strep A) in healthy young adults aged 18 to 25 in Australia. The study aims to test two formulations of the vaccine, one with an Alum adjuvant and the other with AS37, across low, medium, and high doses. This trial is significant as it marks the first human testing of these vaccine formulations, potentially paving the way for new preventive measures against Strep A infections.
GlaxoSmithKline (GSK) is conducting a Phase I clinical study titled A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4172239D. The study aims to investigate the safety, tolerability, and pharmacokinetics of GSK4172239D, a prodrug intended for sickle cell disease patients aged 18 to 50 years.
GSK announced the purchase of 491,631 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, part of an agreement from June 2025, increases GSK’s treasury shares to 234,811,740, with the total number of voting rights remaining at 4,080,572,540. The buyback is a strategic move to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) is conducting a Phase 2a study titled ‘Dose Exploration Study of GSK4532990 in Participants With NASH or Suspected NASH.’ The study aims to evaluate the pharmacokinetics and pharmacodynamics of GSK4532990, a drug intended for treating nonalcoholic steatohepatitis (NASH), and to ensure its safety and tolerability. This research is significant as it could lead to new treatment options for NASH, a liver disease with limited therapeutic solutions.
GlaxoSmithKline (GSK) is conducting a Phase 2b study titled ‘A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)’. The study aims to evaluate the safety and efficacy of sequential therapy using two different doses of DAP/TOM followed by bepirovirsen in patients with chronic hepatitis B, who are already on standard nucleos(t)ide analogue therapy. The goal is to determine the optimal dose of DAP/TOM for future development and assess its contribution to the treatment regimen.
GSK announced the approval of Blenrep combinations in the European Union for treating relapsed or refractory multiple myeloma, based on superior efficacy demonstrated in the DREAMM-7 and DREAMM-8 phase III trials. This approval marks a significant advancement in multiple myeloma treatment, offering a differentiated mechanism of action and broad accessibility, potentially extending remission and survival for patients. The approval positions GSK strongly in the oncology market, with applications for Blenrep under review in major global markets, highlighting its potential impact on patient care and the company’s market positioning.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GlaxoSmithKline (GSK) has announced the purchase of 491,680 of its own ordinary shares as part of its ongoing buyback program. The shares, acquired through Merrill Lynch International, were bought at prices ranging from 1,364.50p to 1,374.50p, with a volume-weighted average price of 1,369.42p. These shares will be held as treasury shares, increasing GSK’s total treasury holdings to 234,320,109 shares. This move is part of a non-discretionary agreement with the broker, which began on June 4, 2025, and has so far seen the purchase of over 16 million shares. The total number of voting rights in the company remains at 4,081,064,171.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK announced that the FDA has extended the review period for the Biologics License Application for Blenrep combinations, used in treating relapsed or refractory multiple myeloma. The extension allows the FDA more time to review additional information, with a new action date set for October 23, 2025. The application is backed by positive results from the DREAMM-7 and DREAMM-8 trials, which demonstrated significant improvements in progression-free survival and overall survival rates. Blenrep combinations are already approved in several countries, and applications are under review in major global markets, potentially impacting GSK’s market positioning and offering new treatment options for multiple myeloma patients.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
GSK has announced the purchase of 506,734 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. These shares will be held as treasury shares, increasing the total to 233,828,429, while the company has 4,081,555,851 shares in issue. This move is part of a non-discretionary agreement to enhance shareholder value, reflecting GSK’s strategic financial management and its impact on voting rights, now at 5.73% for treasury shares.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.